Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.

Abstract: The present invention relates to a binding molecule comprising at least three binding specificities, wherein (a) the first specificity is for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen; (b) (i) the second and third specificity are for CD3 and CD28, respectively; or (ii) the second and third specificity are selected from specificities for CD16, CD56, NKp30, NKp46, 4-1BB and NKG2D; and (c) each binding specificity is provided by one or more binding sites, each binding site being independently provided by (i) a set of six complementarity determining regions (CDRs), wherein said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain; or (ii) a set of three CDRs, wherein said set of three CDRs is comprised in an immunoglobulin domain.

Abstract: The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

Abstract: The invention relates to the identification of monoclonal HIV-1 neutralizing antibodies, such as, but not limited to, antibodies that bind to the CD4 binding site (CD4bs) of HIV-1 gp120, their recombinant expression and purification and uses. In certain aspects, the invention provides a pharmaceutical composition comprising anyone of the antibodies of the invention or fragments thereof or any combination thereof. In certain aspects the invention provides methods to treat or prevent HIV-1 infection in a subject comprising administering to the subject a pharmaceutical composition comprising any one of the inventive antibodies or fragments thereof.

Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Abstract: The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.

Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.

Abstract: The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.

Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.

Abstract: An anti-IL-12 antibody or fragment thereof that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody or fragment thereof, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.

Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.

Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.

Abstract: A method for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody (MEDI4736), alone or in combination with an anti-CTLA4 antibody (Tremelimumab), in a patient identified using a polynucleotide marker of IFNgamma.

Abstract: The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an AFP peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

Abstract: The present invention concerns methods and compositions comprising an anti-IGF-1R antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer. The anti-IGF-1R antibody or fragment may be part of a complex, such as a DOCK-AND-LOCK® (DNL®) (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL® (complex produced by binding interaction between anchor domain moiety of A-kinase anchoring protein and dimerization and docking domain moiety of protein kinase A regulatory subunit) complex. Preferably, the DNL® complex also comprises a second antibody, a second antibody fragment, an affibody or a cytokine. More preferably, the cytokine is interferon-?2b. Most preferably, the second antibody, second fragment or affibody binds to IGF-1R, TROP2 or CEACAM6.

Abstract: In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject with or potentially with atopic dermatitis, at 0.1 to 1000 mg/body/1 day to 12 weeks, preferably at 0.1 to 1000 mg/body/2 weeks, 0.1 to 1000 mg/body/4 weeks, or 0.1 to 1000 mg/body/8 weeks.

Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.

Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

Abstract: The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (NAFLDs) and/or nonalcoholic steatohepatitis (NASH) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing NAFLD/NASH using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.

Abstract: The present invention provides fusion proteins that act on the glucocorticoid-induced TNFR family-related gene (GITR) and OX40 signaling pathway. The proteins of the invention are useful in modulating both regulatory T (Treg) cells and effector T (Teff) cells.

Abstract: Described herein is the development of recombinant single domain antibodies, also known as nanobodies, that may provide better therapeutic results or be useful for diagnostic applications of B-cell lymphomas, or in other applications where an antibody to CD20 may be useful.

Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Abstract: Embodiments of the disclosure include immune cells expressing HER2-specific chimeric antigen receptors (CAR) and treatment of cancer therewith. In specific embodiments, sarcoma or glioblastoma are treated. In specific embodiments, such as for glioblastoma, for example, T-cells expressing a HER2-specific CAR are pp65CMV-specific T cells.

Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.

Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.

Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.

Abstract: The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a polyethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

Abstract: An adapter panel for use with an undercover and canopy for weather protection of a hammock is disclosed. An example includes an undercover having side edges. A canopy with a substantially diamond shape. An adapter panel has a shape corresponding to the shape of the canopy. The adapter panel has a first longitudinal edge and a second longitudinal edge spaced apart by a body of the adapter panel. The adapter panel joins to the undercover along only the first longitudinal edge of the adapter panel. The adapter panel joins to the canopy along only the second longitudinal edge of the adapter panel. The body of the adapter panel joins the undercover to the canopy.

Abstract: The present invention relates to the use of extrusion technology in a process for the low-moisture continuous gelatinisation and the enzymatic hydrolysis of flour to provide a dextrinised product having a dextrose equivalent (DE) of at least 15 and to a process for drying a dextrinised product.

Abstract: Compositions comprising oxidized soy polysaccharide compounds are disclosed herein. Oxidized soy polysaccharide compounds are produced by contacting soy polysaccharide under aqueous conditions with at least one N-oxoammonium salt, periodate compound, and/or peroxide compound.

Abstract: Naphthalimide compounds as used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bone tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.

Abstract: The present invention provides a rubber composition for tire treads, the rubber composition achieving high rubber hardness and 300% modulus at high temperatures, and excellent dry grip properties when formed into a tire, along with a pneumatic tire obtainable by using the same. The rubber composition for tire treads of the present invention contains carbon black and a diene rubber including a carboxy-modified polymer. The carbon black content is from 80 to 150 parts by mass per 100 parts by mass of the diene rubber. The carboxy-modified polymer is obtained by modifying styrene-butadiene rubber (A) with a nitrone compound having carboxy group (B), and the content of the carboxy-modified polymer in the diene rubber is from 10 to 100 mass %. The content of styrene units in styrene-butadiene rubber (A) is at least 36 mass %. The degree of modification of the carboxy-modified polymer is from 0.02 to 4.0 mol %.

Abstract: The present invention relates to an in situ preparation of a redox initiated bimorphological aqueous dispersion of first polymer particles with protuberating phosphorus acid cores and second polymer particles without protuberating cores. The method provides a more efficient way of making compositions for pigmented coating formulations.

Abstract: A method for transitioning a gas phase polymerization reactor between metallocene catalysts is provided. The method comprises first reducing the superficial gas velocity and increasing the height of the fluidized bed within the reactor prior to stopping a feed comprising a first metallocene catalyst. The method further comprises introducing a first polymerization neutralizer to the reactor, wherein the first polymerization reactor does not comprise water, and then introducing a second polymerization neutralizer to the reactor, wherein the second polymerization neutralizer is different from the first polymerization neutralizer. After this, the method comprises purging the reactor with an inert gas and then introducing a feed comprising a second metallocene catalyst to the reactor.

Abstract: Solid adducts comprising MgCl2 and an alcohol ROH in which R is a C1-C20 hydrocarbon group, in which the amount of alcohol ranges from higher than 42% to 60% by weight and the porosity determined with Hg method due to pores up to 1 ?m and expressed in cm3/g, is such that the value of its ratio with the amount of alcohol in percentage falls above the straight line defined by the equation y=?0.0158x+1.03 in which y is the porosity of the adduct and x is the alcohol percentage by weight.

Abstract: Catalyst systems and methods for making and using the same are disclosed. A catalyst composition is provided that includes a catalyst compound supported to form a supported catalyst system, the catalyst compound including: where each of R1, R2, R3, R4, R5, R6, R7 and X are as discussed herein.

Abstract: The present application describes barrier coatings and barrier films comprising copolymers and terpolymers that are soluble in aqueous solutions containing greater than or equal to 50% alcohol. The copolymers and terpolymers comprise at least one olefin derived from isopropenyl acetate and at least one unit derived from vinyl acetate and derivatives thereof. The copolymers and terpolymers are greater than 90% hydrolyzed. Barrier compositions prepared with the copolymers and terpolymers exhibit reduced oxygen transmission rates, good adhesion to substrates, good lamination bond strength, as well as other properties desirable in barrier coatings and barrier films.

Abstract: A halogenated polyisoolefin copolymer is composed of at least one isoolefin monomer, at least one multiolefin monomer, a halogen content of 0.05-2.5 mol %, and a halogenated oligomer content of less than 65% of total oligomer content in the halogenated polyisoolefin copolymer. The copolymer has low halogen content and significantly reduced levels of halogenated oligomers. The copolymer is especially useful in the pharmaceutical and food industries, for example as pharmaceutical and food product seals and closures.

Abstract: The present disclosure relates to a novel metallocene supported catalyst, and a method for preparing a polyolefin using the same. The metallocene supported catalyst according to the present disclosure exhibits a high polymerization activity even when the metallocene compound is supported on a support, thereby showing an excellent activity and preparing a polyolefin having a high molecular weight.

Abstract: The present disclosure relates to a continuous process for the preparation of ethylene homopolymers or ethylene copolymers comprising polymerizing ethylene or copolymerizing ethylene and one or more other olefins in the presence of a chromium catalyst in a gas-phase polymerization reactor which is equipped with a cycle gas line for withdrawing reactor gas from the reactor, leading the reactor gas through a heat-exchanger for cooling and feeding the reactor gas back to the reactor, wherein the polymerization is carried out at a temperature from 30° C. to 130° C. and a pressure of from 0.1 to 10 MPa and an aliphatic carboxylic acid ester having from 8 to 24 carbon atoms is added.

Abstract: The present invention relates to a metallocene complex with a heteroatom-containing ?-ligand, having a chemical structure represented by formula (I) as below: wherein M is a transition metal element from Group 3, Group 4, Group 5 and Group 6 in the periodic table, including lanthanides and actinides; X, being the same as or different from each other, is selected from hydrogen, halogen, an alkyl group R, an alkoxyl group OR, a mercapto group SR, a carboxyl group OCOR, an amino group NR2, a phosphino group PR2, —ORoO— and OSO2CF3; n is an integer from 1 to 4 and is not zero; the charge number resulted from multiplying n by the charge number of X equals to the charge number of the central metal atom M minus 2; Q is a divalent radical; A is a ?-ligand; and Z is a ?-ligand; the process for producing the same; a catalyst system of the same; and use of the catalyst system.

Abstract: A conjugated diene polymer having a high content of cis-1,4-structures with a high activity, a conjugated diene polymer and a modified conjugated diene polymer using the same, a rubber composition for a tire, and a rubber composition for a rubber belt. Described are a catalyst for a conjugated diene polymerization including: a non-metallocene type gadolinium compound (A) represented by the general formula (1); an ionic compound (B) formed of a non-coordinating anion and a cation; and an organic metal compound (C) of an element selected from the group consisting of a group 2, a group 12, and a group 13 of the periodic table, a conjugated diene polymer and a modified conjugated diene polymer obtained using the same, a rubber composition for a tire, and a rubber composition for a rubber belt.

Abstract: This invention relates to new multimodal and/or broad molecular weight high density polyethylene polymers. The polymers may be made in a single reactor, preferably a gas phase reactor using a dual catalyst system comprising a pyridyldiamido transition metal compound, a metallocene compound, a support, and optionally an activator.

Abstract: By controlling the ratio of catalyst components or the type of activator the homogeneity of a polymer produced using a single site catalyst may be improved.